CET – (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the ...
Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2 ...
Home > Pressemitteilung: On the way to curing type 1 diabetes ... MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...